Novel NNRTI AIC292 works well against drug-resistant HIV
New NNRTI MK-1439 interacts with ritonavir but not tenofovir
Dolutegravir shows good efficacy across broad range of patient groups
US PrEP prescriptions more likely to go to Southern women
New tenofovir formulation works equally well with less effect on kidneys and bones
Raltegravir is a good choice for people with HIV undergoing cancer chemotherapy
CD4 gene therapy may enable functional HIV control during treatment interruption
